Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis

Details for Australian Patent Application No. 2001267390 (hide)

Owner Applied Research Systems ARS Holding N.V. Inserm Institut National de la Sante et de la Recherche Medicale

Inventors Chvatchko, Yolande; Tedgui, Alain; Mallat, Ziad

Agent FB Rice

Pub. Number AU-B-2001267390

PCT Pub. Number WO01/85201

Priority 00109606 05.05.00 EP

Filing date 30 April 2001

Wipo publication date 20 November 2001

Acceptance publication date 22 September 2005

International Classifications

C07K 014/54 Peptides having more than 20 amino acids

A61K 039/395 Medicinal preparations containing antigens or antibodies - Antibodies

A61P 009/10 Drugs for disorders of the cardiovascular system

C07K 014/81 Peptides having more than 20 amino acids - Protease inhibitors

A61P 007/02 Drugs for disorders of the blood or the extracellular fluid

C07K 016/24 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 039/00 Medicinal preparations containing antigens or antibodies

Event Publications

22 September 2005 Application Accepted

  Published as AU-B-2001267390

19 January 2006 Standard Patent Sealed

14 January 2010 Assignment Registered

  Applied Research Systems ARS Holding N.V.; INSERM - Institut National de la Sante et de la Recherche Medicale The patent has been assigned to INSERM - Institut National de la Sante et de la Recherche Medicale; Merck Serono SA

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001267391-Ambient stable beverage

2001267389